Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19

PHASE2CompletedINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

March 30, 2020

Primary Completion Date

July 1, 2020

Study Completion Date

January 1, 2021

Conditions
COVID-19
Interventions
DRUG

Hydroxychloroquine

Patients in the hydroxychloroquine arm will receive hydroxychloroquine 400 mg by mouth twice daily for 1 day, then 200 mg by mouth twice daily for 4 days (dose reductions for weight \< 45 kg or GFR (glomerular filtration rate)\<50ml/min). For patients \< 45kg, doses will be halved. For patients with GFR\<50ml/min, the final dose of hydroxychloroquine will not be administered. If the patient has already received hydroxychloroquine prior to randomization (no more than 2 days), the prior doses will count toward the 5-day total.

DRUG

Azithromycin

Patients in the azithromycin arm will receive azithromycin 500 mg on day 1 plus 250 mg daily on days 2-5 (may be administered intravenously per clinician preference). If the patient has already received azithromycin prior to randomization (no more than 2 days), the prior doses will count toward the 5-day total.

Trial Locations (2)

84107

Intermountain Medical Center, Murray

84112

University of Utah, Salt Lake City

All Listed Sponsors
collaborator

University of Utah

OTHER

lead

Intermountain Health Care, Inc.

OTHER

NCT04329832 - Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19 | Biotech Hunter | Biotech Hunter